Evidence map›Paper›PMID 35359969›Full record

ArticleFrontiers in immunology2022

Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.

Ivan Odak, Christian R Schultze-Florey, Swantje I Hammerschmidt, Christiane Ritter, Stefanie Willenzon, Michaela Friedrichsen, Inga Ravens, Ruth Sikora, Lâle M Bayir, Rodrigo Gutierrez Jauregui and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Ivan OdakInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Christian R Schultze-FloreyInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Swantje I HammerschmidtInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Christiane RitterInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Stefanie WillenzonInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Michaela FriedrichsenInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Inga RavensInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Ruth SikoraInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Lâle M BayirInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Rodrigo Gutierrez JaureguiInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Günter BernhardtInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Metodi V StankovClinic Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Anne CossmannClinic Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Guido HansenInstitute of Biochemistry, University of Lübeck, Lübeck, Germany.
Thomas KreyInstitute of Biochemistry, University of Lübeck, Lübeck, Germany.
Markus CornbergCluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
Christian KoeneckeInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Georg M N BehrensClinic Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Berislav BošnjakInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Reinhold FörsterInstitute of Immunology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEGerman Center for Infection Research · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluating long-term protection against SARS-CoV-2 variants of concern in convalescing individuals is of high clinical relevance. In this prospective study of a cohort of 46 SARS-CoV-2 patients infected with the Wuhan strain of SARS-CoV-2 we longitudinally analyzed changes in humoral and cellular immunity upon early and late convalescence. Antibody neutralization capacity was measured by surrogate virus neutralization test and cellular responses were investigated with 31-colour spectral flow cytometry. Spike-specific, isotype-switched B cells developed already during the disease phase, showed a memory phenotype and did not decrease in numbers even during late convalescence. Otherwise, no long-lasting perturbations of the immune compartment following COVID-19 clearance were observed. During convalescence anti-Spike (S1) IgG antibodies strongly decreased in all patients. We detected neutralizing antibodies against the Wuhan strain as well as the Alpha and Delta but not against the Beta, Gamma or Omicron variants for up to 7 months post COVID-19. Furthermore, correlation analysis revealed a strong association between sera anti-S1 IgG titers and their neutralization capacity against the Wuhan strain as well as Alpha and Delta. Overall, our data suggest that even 7 month after the clearance of COVID-19 many patients possess a protective layer of immunity, indicated by the persistence of Spike-specific memory B cells and by the presence of neutralizing antibodies against the Alpha and Delta variants. However, lack of neutralizing antibodies against the Beta, Gamma and Omicron variants even during the peak response is of major concern as this indicates viral evasion of the humoral immune response.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingConvalescenceHumansImmunity, HumoralImmunoglobulin GProspective StudiesSpike Glycoprotein, CoronavirusAntibodies, NeutralizingImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodiesB cellsdeltaomicronprotectionspikevariants of concern

Identifiers

PMID35359969
PMCPMC8964088
OpenAlexW4221055861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.